Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organizational Stressors, Burnout, and Mental Health Outcomes Among Local Government Employees During Disaster Response.

Journal of occupational and environmental medicine·2026
Same author

Dexamethasone-induced 3D cortical spheroid model of stress-related neuroplasticity impairment.

Scientific reports·2026
Same author

Korean Medication Algorithm Project for Depressive Disorder 2025: Comparisons with Other Treatment Guidelines.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same author

Prevalence and burden of anhedonia among patients with major depressive disorder in South Korea: A cross-sectional, observational study.

PloS one·2025
Same author

Korean Medication Algorithm for Depressive Disorder 2025, Fifth Revision: An Executive Summary.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2025
Same author

Establishment of a Depression Model Using Dexamethasone-treated Three-dimensional Cultured Rat Cortical Cells.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2025
Same journal

Systematic Mental Health Care for Airline Pilots: Addressing Rare but Catastrophic Safety Outcomes.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same journal

Dose Response Relationships of Loneliness and Insomnia With Subclinical Hikikomori Among College Students: A Multicentre Survey.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same journal

Advising on Antidepressant Use in Pregnancy: Are We All on the Same Page?

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same journal

Concerns About Self-Safety or Own Emotional Regulation in the Home are Both Associated With Suicidal Ideation: A Risk Factor Warranting Research and Policy Attention.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same journal

Inter-Relationships Between Depressive Symptoms And Sleep Problems Among Older Adults With Depression: Findings of a National Survey in the USA.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same journal

Gender Differences in the Prevalence and Correlates of Post-Stroke Depression Among Older Stroke Survivors: Findings From a National Survey in China.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Korean medication algorithm for bipolar disorder: second revision.

Young Chul Shin1, Kyung Joon Min, Bo-Hyun Yoon

  • 1Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Korea.

Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists
|July 17, 2013
PubMed
Summary
This summary is machine-generated.

Treatment guidelines for bipolar disorder have been updated based on new data and expert consensus. The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was revised to reflect these changes in first-line treatment strategies.

Keywords:
algorithmbipolar disorderrevisiontreatment guideline

Related Experiment Videos

Last Updated: May 9, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was initially developed in 2002 and revised in 2006.
  • Significant new data necessitated a further revision of the KMAP-BP 2006 guidelines.

Purpose of the Study:

  • To update the Korean Medication Algorithm Project for Bipolar Disorder based on recent clinical data and expert opinion.
  • To establish current first-line treatment recommendations for various bipolar disorder episodes.

Main Methods:

  • A questionnaire was developed based on KMAP-BP 2006 and new data.
  • The revised questionnaire was distributed to 94 experts in the field.
  • Responses were collected from 65 experts.

Main Results:

  • First-line treatment for acute manic episodes involves a combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP).
  • For hypomanic episodes, MS monotherapy is recommended.
  • Treatment strategies for bipolar depression vary, including combinations of MS, AAP, and antidepressants (AD), with specific agents like lithium, lamotrigine, valproic acid, quetiapine, olanzapine, and aripiprazole highlighted.
  • Maintenance treatment recommendations include MS with AAP combination or MS monotherapy.

Conclusions:

  • Expert consensus on the initial steps of bipolar disorder treatment has evolved since the 2002 and 2006 KMAP-BP studies.
  • The revised algorithm reflects current best practices in managing bipolar disorder.